Susquehanna International Group, LLP Equillium, Inc. Call Options Transaction History

Susquehanna International Group, LLP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	BUY	$0.66 - $2.33 $9,042 - $31,921	13,700 Added 87.82%	29,300 $20,000
Q1 2024 May 07, 2024	BUY	$0.73 - $3.0 $1,679 - $6,900	2,300 Added 17.29%	15,600 $36,000
Q4 2023 Feb 14, 2024	SELL	$0.48 - $0.74 $48 - $74	-100 Reduced 0.75%	13,300 $9,000
Q3 2023 Nov 14, 2023	BUY	$0.72 - $0.9 $9,648 - $12,060	13,400 New	13,400 $9,000
Q4 2022 Feb 14, 2023	SELL	$0.83 - $2.26 $23,655 - $64,409	-28,500 Reduced 44.12%	36,100 $38,000
Q3 2022 Nov 14, 2022	BUY	$1.93 - $3.14 $124,678 - $202,844	64,600 New	64,600 $143,000

11.5M

38.1K

Ticker EQ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,352,100
Market Cap $47.1M
Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.